Are certain drugs associated with enhanced mortality in COVID-19?

Goldstein, Mark R.; Graeber, Charles

doi:10.1093/qjmed/hcaa103

Cited by 34 publications

(37 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They have an antiinflammatory effect, which is mainly mediated through pathways that lead to inhibition of nuclear factor kappa (NF-kB) [62]. Like ACEIs/ARBs, statins upregulate tissue ACE2 [63]. The CORONADO study did not find a protective role of statins on the primary endpoint of endotracheal intubation or death in COVID-19 patients with diabetes mellitus [58•].…”

Section: Dyslipidaemiamentioning

confidence: 99%

Vascular Events, Vascular Disease and Vascular Risk Factors—Strongly Intertwined with COVID-19

Scutelnic

Heldner

2020

Curr Treat Options Neurol

View full text Add to dashboard Cite

Purpose of review To elucidate the intertwining of vascular events, vascular disease and vascular risk factors and COVID-19. Recent findings Strokes are a leading cause of disability and death worldwide. Vascular risk factors are important drivers of strokes. There are unmodifiable vascular risk factors such as age and ethnicity and modifiable vascular risk factors. According to the INTERSTROKE study, the 10 most frequent modifiable vascular risk factors are arterial hypertension, physical inactivity, overweight, dyslipidaemia, smoking, unhealthy diet, cardiac pathologies, diabetes mellitus, stress/depression and overconsumption of alcohol. Also, infection and inflammation have been shown to increase the risk of stroke. There is high-quality evidence for the clinical benefits of optimal primary and secondary stroke prevention. The COVID-19 pandemic brought a new perspective to this field. Vascular events, vascular disease and vascular risk factors—and COVID-19—are strongly intertwined. An increased risk of vascular events—by multifactorial mechanisms—has been observed in COVID-19 patients. Also, a higher rate of infection with COVID-19, severe COVID-19 and bad outcome has been demonstrated in patients with pre-existing vascular disease and vascular risk factors. Summary At present, we suggest that regular interactions between healthcare professionals and patients should include education on COVID-19 and on primary and secondary vascular prevention in order to reduce the burden of disease in our ageing populations.

show abstract

Section: Dyslipidaemiamentioning

confidence: 99%

Vascular Events, Vascular Disease and Vascular Risk Factors—Strongly Intertwined with COVID-19

Scutelnic

Heldner

2020

Curr Treat Options Neurol

View full text Add to dashboard Cite

show abstract

“…In the era of the COVID-19 pandemic, such a drug effect may be considered as potentially worrying [10]. In this context, it was recently even suggested that ARBs could be replaced with ACE inhibitors and that statin treatment may be discontinued during the pandemic, particularly in primary prevention settings [11].…”

mentioning

confidence: 99%

Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic

Katsiki¹,

Banach²,

Mikhailidis³

2020

aoms

View full text Add to dashboard Cite

“…Finally, for the COVID-19 outbreak, although some US hospitals included statins in COVID-19 treatment 6 and some proposed their use for this condition, 13 some others worry regarding statininduced increase in IL-18 and deterioration of SARS-CoV-2-induced ARDS and mortality. 21…”

Section: E T T E R S T O T H E E D I T O Rmentioning

confidence: 99%